Όλο το DSpace

Εμφάνιση απλής εγγραφής

Revisiting bleomycin from pathophysiology to safe clinical use

dc.creatorFroudarakis, M.en
dc.creatorHatzimichael, E.en
dc.creatorKyriazopoulou, L.en
dc.creatorLagos, K.en
dc.creatorPappas, P.en
dc.creatorTzakos, A. G.en
dc.creatorKaravasilis, V.en
dc.creatorDaliani, D.en
dc.creatorPapandreou, C.en
dc.creatorBriasoulis, E.en
dc.date.accessioned2015-11-23T10:26:47Z
dc.date.available2015-11-23T10:26:47Z
dc.date.issued2013
dc.identifier10.1016/j.critrevonc.2012.12.003
dc.identifier.issn1040-8428
dc.identifier.urihttp://hdl.handle.net/11615/27578
dc.description.abstractBleomycin is a key component of curative chemotherapy regimens employed in the treatment of curable cancers, such as Hodgkin lymphoma (HL) and testicular germ-cell tumours (GCT), yet its use may cause bleomycin-induced lung injury (BILI), which is associated with significant morbidity and a mortality rate of 1-3%. Diagnosis of BILI is one of exclusion and physicians involved in the care of HL and GCT patients should be alerted. Pharmacogenomic studies could contribute towards the identification of molecular predictors of bleomycin toxicity on the aim to optimize individual use of bleomycin. We review all existing data on bleomycin's most recent integrated chemical biology, molecular pharmacology and mature clinical data and provide guidelines for its safe clinical use. (C) 2012 Elsevier Ireland Ltd. All rights reserved.en
dc.source.uri<Go to ISI>://WOS:000320750900008
dc.subjectBleomycinen
dc.subjectHodgkin's Lymphomaen
dc.subjectTesticular germ-cell tumouren
dc.subjectLung injuryen
dc.subjectTherapeuticsen
dc.subjectSafe clinical useen
dc.subjectToxicityen
dc.subjectGERM-CELL TUMORSen
dc.subjectINDUCED PULMONARY TOXICITYen
dc.subjectCANCER COOPERATIVE GROUPen
dc.subjectINDUCED LUNG DAMAGEen
dc.subjectINDUCED PNEUMONITISen
dc.subjectHODGKINS-LYMPHOMAen
dc.subjectCOMBINATIONen
dc.subjectCHEMOTHERAPYen
dc.subjectRANDOMIZED-TRIALen
dc.subjectCISPLATIN CHEMOTHERAPYen
dc.subjectEUROPEANen
dc.subjectORGANIZATIONen
dc.subjectOncologyen
dc.subjectHematologyen
dc.titleRevisiting bleomycin from pathophysiology to safe clinical useen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής